EcoDrugPlus

Yes Proto-Oncogene 1, Src Family Tyrosine Kinase

Ensembl ID : ENSMPUG00000005394
Gene Symbol: YES1
2 Cross references
268 Possible Orthologues:

Acetylcholinesterase (Cartwright Blood Group)

Ensembl ID : ENSMPUG00000015841
Gene Symbol: ACHE
2 Cross references
233 Possible Orthologues:

Activin A Receptor Like Type 1

Ensembl ID : ENSMPUG00000007859
Gene Symbol: ACVRL1
2 Cross references
353 Possible Orthologues:

Activin A Receptor Type 2b

Ensembl ID : ENSMPUG00000002620
Gene Symbol: ACVR2B
2 Cross references
257 Possible Orthologues:

Adenosine A1 Receptor

Ensembl ID : ENSMPUG00000011510
Gene Symbol: ADORA1
2 Cross references
269 Possible Orthologues:

Adenosine A2a Receptor

Ensembl ID : ENSMPUG00000002874
Gene Symbol: ADORA2A
4 Cross references
260 Possible Orthologues:

Adenosine A2b Receptor

Ensembl ID : ENSMPUG00000010258
Gene Symbol: ADORA2B
2 Cross references
200 Possible Orthologues:

Adenosine A3 Receptor

Ensembl ID : ENSMPUG00000004839
Gene Symbol: ADORA3
2 Cross references
89 Possible Orthologues:

Adenosine Deaminase

Ensembl ID : ENSMPUG00000017664
Gene Symbol: ADA
2 Cross references
216 Possible Orthologues:

Adrenoceptor Alpha 1a

Ensembl ID : ENSMPUG00000000865
Gene Symbol: ADRA1A
2 Cross references
201 Possible Orthologues:

Adrenoceptor Alpha 1b

Ensembl ID : ENSMPUG00000013327
Gene Symbol: ADRA1B
2 Cross references
263 Possible Orthologues:

Adrenoceptor Alpha 1d

Ensembl ID : ENSMPUG00000008569
Gene Symbol: ADRA1D
2 Cross references
194 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).